Search

Your search keyword '"Bezzio C."' showing total 297 results
Start Over Author "Bezzio C."
297 results on '"Bezzio C."'

1. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., Bezzio, C., Bossa, F., Privitera, A.C., Marchi, S., Roselli, J., Mazzuoli, S., Geccherle, A., Soriano, A., Principi, M.B., Viola, A., Sarpi, L., Cappello, M., D'Incà, R., Mastronardi, M., Bodini, G., Guerra, M., Benedetti, A., Romano, M., Cicala, M., Di Sabatino, A., Scaldaferri, F., De Rosa, T., Giardino, A.M., Germano, V., Orlando, A., and Armuzzi, A.

Published
2024
Full Text
View/download PDF

2. Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study

Author

Macaluso, F, Principi, M, Facciotti, F, Contaldo, A, Todeschini, A, Saibeni, S, Bezzio, C, Castiglione, F, Nardone, O, Spagnuolo, R, Fantini, M, Riguccio, G, Conforti, S, Caprioli, F, Vigano, C, Felice, C, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Bossa, F, Guerra, M, Ventimiglia, M, Casa, A, Rizzo, G, Orlando, A, Amato, A, Ascolani, M, Calabrese, G, Comberlato, M, De Bona, M, Demarzo, M, Doldo, P, Dragoni, G, Furfaro, F, Laffusa, A, Martino, G, Mulinacci, G, Olmo, O, O'Sed, N, Paba, S, Radice, S, Renna, S, Ribaldone, D, MacAluso F. S., Principi M., Facciotti F., Contaldo A., Todeschini A., Saibeni S., Bezzio C., Castiglione F., Nardone O. M., Spagnuolo R., Fantini M. C., Riguccio G., Conforti S., Caprioli F., Vigano C., Felice C., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Bossa F., Guerra M., Ventimiglia M., Casa A., Rizzo G., Orlando A., Amato A., Ascolani M., Calabrese G., Comberlato M., De Bona M., Demarzo M. G., Doldo P., Dragoni G., Furfaro F., Laffusa A., Martino G., Mulinacci G., Olmo O., O'Sed N. P., Paba S., Radice S., Renna S., Ribaldone D. G., Macaluso, F, Principi, M, Facciotti, F, Contaldo, A, Todeschini, A, Saibeni, S, Bezzio, C, Castiglione, F, Nardone, O, Spagnuolo, R, Fantini, M, Riguccio, G, Conforti, S, Caprioli, F, Vigano, C, Felice, C, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Bossa, F, Guerra, M, Ventimiglia, M, Casa, A, Rizzo, G, Orlando, A, Amato, A, Ascolani, M, Calabrese, G, Comberlato, M, De Bona, M, Demarzo, M, Doldo, P, Dragoni, G, Furfaro, F, Laffusa, A, Martino, G, Mulinacci, G, Olmo, O, O'Sed, N, Paba, S, Radice, S, Renna, S, Ribaldone, D, MacAluso F. S., Principi M., Facciotti F., Contaldo A., Todeschini A., Saibeni S., Bezzio C., Castiglione F., Nardone O. M., Spagnuolo R., Fantini M. C., Riguccio G., Conforti S., Caprioli F., Vigano C., Felice C., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Bossa F., Guerra M., Ventimiglia M., Casa A., Rizzo G., Orlando A., Amato A., Ascolani M., Calabrese G., Comberlato M., De Bona M., Demarzo M. G., Doldo P., Dragoni G., Furfaro F., Laffusa A., Martino G., Mulinacci G., Olmo O., O'Sed N. P., Paba S., Radice S., Renna S., and Ribaldone D. G.

Abstract

This prospective study reported 2 key results: (1) lack of seroconversion following 2 doses of COVID-19 vaccines is an independent predictor of SARS-CoV-2 infection; (2) treatments for IBD were not associated with increased risk of SARS-CoV-2 infection.

Published
2024

3. OC.03.11: FACTORS CORRELATED WITH TRANSMURAL HEALING IN PATIENTS WITH CROHN'S DISEASE IN LONG-TERM CLINICAL REMISSION ON ANTI-TNF MEDICATION

Author

Maconi, G., primary, Lepore, F., additional, Saleh, A., additional, Saibeni, S., additional, Bezzio, C., additional, Cheli, S., additional, Massari, A., additional, Gridavilla, D., additional, Ferretti, F., additional, Cannatelli, R., additional, Di Sabatino, A., additional, Ardizzone, S., additional, Clementi, E., additional, and Abraham, B., additional

Published
2024
Full Text
View/download PDF

5. BOC.02.8: DEFINING DIAGNOSTIC ULTRASONOGRAPHIC PARAMETERS IN ULCERATIVE COLITIS: A LONGITUDINAL PROSPECTIVE MULTICENTER STUDY

Author

Zorzi, F., primary, Fraquelli, M., additional, Bezzio, C., additional, Castiglione, F., additional, Rispo, A., additional, Allocca, M., additional, Cuccagna, E., additional, Furfaro, F., additional, Caprioli, F., additional, Ventura, M., additional, Testa, A., additional, Saibeni, S., additional, Maconi, G., additional, De Cristofaro, E., additional, Monteleone, G., additional, and Calabrese, E., additional

Published
2024
Full Text
View/download PDF

6. The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus

Author

Macaluso, F, Caprioli, F, Benedan, L, Bezzio, C, Caporali, R, Cauli, A, Chimenti, M, Ciccia, F, D'Angelo, S, Fantini, M, Festa, S, Iannone, F, Lubrano, E, Mariani, P, Papi, C, Provenzano, G, Pugliese, D, Rispo, A, Saibeni, S, Salvarani, C, Variola, A, Zenga, M, Armuzzi, A, Orlando, A, Gerli, R, Macaluso, Fabio Salvatore, Caprioli, Flavio, Benedan, Laura, Bezzio, Cristina, Caporali, Roberto, Cauli, Alberto, Chimenti, Maria Sole, Ciccia, Francesco, D'Angelo, Salvatore, Fantini, Massimo Claudio, Festa, Stefano, Iannone, Florenzo, Lubrano, Ennio, Mariani, Paolo, Papi, Claudio, Provenzano, Giuseppe, Pugliese, Daniela, Rispo, Antonio, Saibeni, Simone, Salvarani, Carlo, Variola, Angela, Zenga, Mariangela, Armuzzi, Alessandro, Orlando, Ambrogio, Gerli, Roberto, Macaluso, F, Caprioli, F, Benedan, L, Bezzio, C, Caporali, R, Cauli, A, Chimenti, M, Ciccia, F, D'Angelo, S, Fantini, M, Festa, S, Iannone, F, Lubrano, E, Mariani, P, Papi, C, Provenzano, G, Pugliese, D, Rispo, A, Saibeni, S, Salvarani, C, Variola, A, Zenga, M, Armuzzi, A, Orlando, A, Gerli, R, Macaluso, Fabio Salvatore, Caprioli, Flavio, Benedan, Laura, Bezzio, Cristina, Caporali, Roberto, Cauli, Alberto, Chimenti, Maria Sole, Ciccia, Francesco, D'Angelo, Salvatore, Fantini, Massimo Claudio, Festa, Stefano, Iannone, Florenzo, Lubrano, Ennio, Mariani, Paolo, Papi, Claudio, Provenzano, Giuseppe, Pugliese, Daniela, Rispo, Antonio, Saibeni, Simone, Salvarani, Carlo, Variola, Angela, Zenga, Mariangela, Armuzzi, Alessandro, Orlando, Ambrogio, and Gerli, Roberto

Abstract

Spondyloarthritis (SpA) is the most frequent extraintestinal manifestation in patients with inflammatory bowel diseases (IBD). When IBD and spondyloarthritis coexist, musculoskeletal and intestinal disease features should be considered when planning a therapeutic strategy. Treatment options for IBD and SpA have expanded enormously over the last few years, but randomized controlled trials with specific endpoints focused on SpA are not available in the IBD setting. To address this important clinical topic, the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and the Italian Society of Rheumatology (SIR) jointly planned to draw updated therapeutic recommendations for IBD-associated SpA using a pseudo-Delphi method. This document presents the official recommendations of IG-IBD and SIR on the management of IBD-associated SpA in the form of 34 statements and 4 therapeutic algorithms. It is intended to be a reference guide for gastroenterologists and rheumatologists dealing with IBD-associated SpA.

Published
2024

7. DOP88 Lipids drive myofibroblast activation and the epithelial-mesenchymal transition process in Crohn’s Disease

Author

Rizzo, G, primary, Wozny, M, additional, Pineda Chavez, S E, additional, Mori, G, additional, Carriles Linares, A, additional, Morosi, L, additional, Martano, G, additional, Ghisletti, S M L, additional, Gandolfi, F, additional, Vallelonga, V, additional, Loy, L, additional, Bezzio, C, additional, Spaggiari, P, additional, Dal Buono, A, additional, Gabbiadini, R, additional, Carvello, M, additional, Spinelli, A, additional, Repici, A, additional, Armuzzi, A, additional, and Vetrano, S, additional

Published
2024
Full Text
View/download PDF

10. P055 GPR43 and GPR84 play a crucial role in supporting perianal fistula formation and disease progression in Crohn’s Disease

Author

Rubbino, F, primary, Di Cristofaro, A, additional, Wozny, M, additional, Rizzo, G, additional, Pineda Chavez, S E, additional, Converso, G, additional, Heijink, M, additional, Giera, M, additional, Maroli, A, additional, Bezzio, C, additional, Loy, L, additional, Carvello, M, additional, Spinelli, A, additional, Laghi, L, additional, Repici, A, additional, Armuzzi, A, additional, and Vetrano, S, additional

Published
2024
Full Text
View/download PDF

11. P921 Maintenance of clinical, biochemical and transmural remission in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab

Author

Piazza O Sed, N, primary, Maregatti, M C, additional, Pessarelli, T, additional, Viganò, C, additional, Conforti, F, additional, Noviello, D, additional, Bezzio, C, additional, Amoroso, C, additional, Molteni, C, additional, Anolli, M P, additional, Pirola, L, additional, Saibeni, S, additional, Fraquelli, M, additional, Vecchi, M, additional, and Caprioli, F, additional

Published
2024
Full Text
View/download PDF

12. P227 The learning curve for using intestinal ultrasonography

Author

Bezzio, C, primary, Saibeni, S, additional, Vernero, M, additional, Furfaro, F, additional, Monteleone, M, additional, Ribaldone, D, additional, Fiorino, G, additional, Brinch, D, additional, Friedman, A B, additional, Scalvini, D, additional, and Maconi, G, additional

Published
2024
Full Text
View/download PDF

13. P079 Low-intensity Pulsed Ultrasound reflects the status of mucosal injury and repair through stage-specific miRNAs in experimental model of Ulcerative Colitis

Author

Pineda Chavez, S E, primary, Carriles Linares, A, additional, Rizzo, G, additional, Wozny, M, additional, Cafarelli, A, additional, Mori, G, additional, Sorriento, A, additional, Loy, L, additional, Dal Buono, A, additional, Gabbiadini, R, additional, Bezzio, C, additional, Lucchetti, D, additional, Sgambato, A, additional, Ricotti, L, additional, Repici, A, additional, Armuzzi, A, additional, and Vetrano, S, additional

Published
2024
Full Text
View/download PDF

14. Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study

Author

Macaluso, F, Principi, M, Facciotti, F, Contaldo, A, Todeschini, A, Saibeni, S, Bezzio, C, Castiglione, F, Nardone, O, Spagnuolo, R, Fantini, M, Riguccio, G, Caprioli, F, Vigano, C, Felice, C, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Mannino, M, Rizzo, G, Orlando, A, Amato, A, Ascolani, M, Calabrese, G, Casa, A, Comberlato, M, Conforti, F, De Bona, M, Demarzo, M, Doldo, P, Dragoni, G, Furfaro, F, Mulinacci, G, Olmo, O, O'Sed, N, Paba, S, Radice, S, Renna, S, Ribaldone, D, Rizzuto, G, Macaluso F. S., Principi M., Facciotti F., Contaldo A., Todeschini A., Saibeni S., Bezzio C., Castiglione F., Nardone O. M., Spagnuolo R., Fantini M. C., Riguccio G., Caprioli F., Vigano C., Felice C., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Mannino M., Rizzo G., Orlando A., Amato A., Ascolani M., Calabrese G., Casa A., Comberlato M., Conforti F. S., De Bona M., Demarzo M. G., Doldo P., Dragoni G., Furfaro F., Mulinacci G., Olmo O., O'Sed N. P., Paba S., Radice S., Renna S., Ribaldone D. G., Rizzuto G., Macaluso, F, Principi, M, Facciotti, F, Contaldo, A, Todeschini, A, Saibeni, S, Bezzio, C, Castiglione, F, Nardone, O, Spagnuolo, R, Fantini, M, Riguccio, G, Caprioli, F, Vigano, C, Felice, C, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Mannino, M, Rizzo, G, Orlando, A, Amato, A, Ascolani, M, Calabrese, G, Casa, A, Comberlato, M, Conforti, F, De Bona, M, Demarzo, M, Doldo, P, Dragoni, G, Furfaro, F, Mulinacci, G, Olmo, O, O'Sed, N, Paba, S, Radice, S, Renna, S, Ribaldone, D, Rizzuto, G, Macaluso F. S., Principi M., Facciotti F., Contaldo A., Todeschini A., Saibeni S., Bezzio C., Castiglione F., Nardone O. M., Spagnuolo R., Fantini M. C., Riguccio G., Caprioli F., Vigano C., Felice C., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Mannino M., Rizzo G., Orlando A., Amato A., Ascolani M., Calabrese G., Casa A., Comberlato M., Conforti F. S., De Bona M., Demarzo M. G., Doldo P., Dragoni G., Furfaro F., Mulinacci G., Olmo O., O'Sed N. P., Paba S., Radice S., Renna S., Ribaldone D. G., and Rizzuto G.

Abstract

Background: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. Aims: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) Methods: Effectiveness and Safety of COVID-19 Vaccine in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs). Results: 1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reported for most IBD patients, even if with a lesser rate compared with HCs (92.1% vs. 97.9%; p<0.001). HCs had higher antibody concentrations (median OD 8.72 [IQR 5.2-14-2]) compared to the whole cohort of IBD patients (median OD 1.54 [IQR 0.8-3.6]; p<0.001) and the subgroup of IBD patients (n=280) without any treatment or on aminosalicylates only (median OD 1.72 [IQR 1.0–4.1]; p<0.001). Conclusions: Although most IBD patients showed seropositivity after COVID-19 vaccines, the magnitude of the humoral response was significantly lower than in HCs. Differently from other studies, these findings seem to be mostly unrelated to the use of immune-modifying treatments (ClinicalTrials.govID:NCT04769258).

Published
2023

15. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., primary, Bezzio, C., additional, Bossa, F., additional, Privitera, A.C., additional, Marchi, S., additional, Roselli, J., additional, Mazzuoli, S., additional, Geccherle, A., additional, Soriano, A., additional, Principi, M.B., additional, Viola, A., additional, Sarpi, L., additional, Cappello, M., additional, D'Incà, R., additional, Mastronardi, M., additional, Bodini, G., additional, Guerra, M., additional, Benedetti, A., additional, Romano, M., additional, Cicala, M., additional, Sabatino, A. Di, additional, Scaldaferri, F., additional, De Rosa, T., additional, Giardino, A.M., additional, Germano, V., additional, Orlando, A., additional, and Armuzzi, A., additional

Published
2023
Full Text
View/download PDF

16. Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison study

Author

Cassinotti, A, Mezzina, N, De Silvestri, A, Di Paolo, D, Lenti, M, Bezzio, C, Stradella, D, Mauri, M, Zadro, V, Ricci, C, Casini, V, Radice, E, Massari, A, Maconi, G, Saibeni, S, Caprioli, F, Tari, R, Fichera, M, Cortelezzi, C, Parravicini, M, Tinelli, C, Testoni, P, Pace, F, Segato, S, Invernizzi, P, Occhipinti, P, Manes, G, Di Sabatino, A, Pastorelli, L, Vecchi, M, Ardizzone, S, Cassinotti A., Mezzina N., De Silvestri A., Di Paolo D., Lenti M. V., Bezzio C., Stradella D., Mauri M., Zadro V., Ricci C., Casini V., Radice E., Massari A., Maconi G., Saibeni S., Caprioli F., Tari R., Fichera M., Cortelezzi C. C., Parravicini M., Tinelli C., Testoni P. A., Pace F., Segato S., Invernizzi P., Occhipinti P., Manes G., Di Sabatino A., Pastorelli L., Vecchi M., Ardizzone S., Cassinotti, A, Mezzina, N, De Silvestri, A, Di Paolo, D, Lenti, M, Bezzio, C, Stradella, D, Mauri, M, Zadro, V, Ricci, C, Casini, V, Radice, E, Massari, A, Maconi, G, Saibeni, S, Caprioli, F, Tari, R, Fichera, M, Cortelezzi, C, Parravicini, M, Tinelli, C, Testoni, P, Pace, F, Segato, S, Invernizzi, P, Occhipinti, P, Manes, G, Di Sabatino, A, Pastorelli, L, Vecchi, M, Ardizzone, S, Cassinotti A., Mezzina N., De Silvestri A., Di Paolo D., Lenti M. V., Bezzio C., Stradella D., Mauri M., Zadro V., Ricci C., Casini V., Radice E., Massari A., Maconi G., Saibeni S., Caprioli F., Tari R., Fichera M., Cortelezzi C. C., Parravicini M., Tinelli C., Testoni P. A., Pace F., Segato S., Invernizzi P., Occhipinti P., Manes G., Di Sabatino A., Pastorelli L., Vecchi M., and Ardizzone S.

Abstract

Objectives Comparative trials among biological drugs for the treatment of ulcerative colitis (UC) provided conflicting results. After patent expire of infliximab originator, adalimumab, infliximab biosimilar, golimumab and vedolizumab have been approved in Italy. We compared the efficacy of these four biologics in UC according to the concept of continuous clinical remission (CCR). Methods In a retrospective, multicentre study, all UC patients treated with adalimumab, infliximab biosimilar, golimumab or vedolizumab between 2014 and 2019 were included. All drugs were compared to each other according to the 1-year CCR rate, defined as Mayo partial score ≤2, with bleeding subscore = 0, without any relapse or optimization with dose escalation, topical treatments or steroid use after first clinical remission. Results Four-hundred sixteen patients (adalimumab = 90, infliximab biosimilar = 105, golimumab = 79, vedolizumab = 142) were included. CCR was achieved in similar percentages among the groups (33%, 37%, 28%, 37%, respectively). All drugs were equivalent in biologic-naive patients, while vedolizumab was better than a second anti-TNF in prior anti-TNF agent failures. No differences were found according to type of adverse events or severe adverse events. Conclusions Based on a strict definition of clinical remission, all biologics appear equally effective at 1 year. Changing to vedolizumab is more effective than switching to another anti-TNF in TNF failures.

Published
2022

17. OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY

Author

Macaluso, F.S., primary, Principi, M., additional, Facciotti, F., additional, Contaldo, A., additional, Todeschini, A., additional, Saibeni, S., additional, Bezzio, C., additional, Castiglione, F., additional, Nardone, O., additional, Spagnuolo, R., additional, Fantini, M., additional, Riguccio, G., additional, Conforti, F., additional, Caprioli, F., additional, Vigano, C., additional, Felice, C., additional, Fiorino, G., additional, Correale, C., additional, Bodini, G., additional, Milla, M., additional, Scardino, G., additional, Vernero, M., additional, Desideri, F., additional, Bossa, F., additional, Guerra, M., additional, Ventimiglia, M., additional, Mannino, M., additional, Rizzo, G., additional, and Orlando, A., additional

Published
2023
Full Text
View/download PDF

18. P605 Real life efficacy of tofacitinib in different situation in ulcerative colitis: a retrospective worldwide multicentre collaborative study

Author

Resál, T, primary, Bacsur, P, additional, Bor, R, additional, Bálint, A, additional, Katsanos, K, additional, Michalopoylos, G, additional, Ribaldone, D G, additional, Attauabi, M, additional, Mirabella, Z, additional, Yanai, H, additional, Bezzio, C, additional, Castiglione, F, additional, Bar-Gil Shitrit, A, additional, Pugliese, D, additional, Lakatos, P L, additional, Savarino, E, additional, Lukáš, M, additional, Franko, M, additional, Chashkova, E, additional, Molander, P, additional, Nancey, S, additional, Bannon, L, additional, Krznaric, Z, additional, Filip, R, additional, Szamosi, T, additional, Kaštylová, K, additional, Sarlós, P, additional, Ami-Barak, H, additional, Rispo, A, additional, Limdi, J, additional, Kagramanova, A, additional, Szepes, Z, additional, Farkas, K, additional, and Molnár, T, additional

Published
2023
Full Text
View/download PDF

19. P455 Comparison of two strategies for the management of post-operative recurrence in Crohn’s disease patients with one clinical risk factor: a multicentre IG-IBD study

Author

Dragoni, G, primary, Castiglione, F, additional, Bezzio, C, additional, Pugliese, D, additional, Spagnuolo, R, additional, Viola, A, additional, Cocomazzi, F, additional, Aratari, A, additional, Savarino, E V, additional, Balestrieri, P, additional, Onali, S, additional, Viganò, C, additional, Ribaldone, D G, additional, Innocenti, T, additional, Testa, A, additional, Saibeni, S, additional, Privitera, G, additional, Milla, M, additional, Armuzzi, A, additional, Fantini, M C, additional, and Fiorino, G, additional

Published
2023
Full Text
View/download PDF

20. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study

Author

Pugliese, D., Privitera, G., Crispino, F., Mezzina, N., Castiglione, F., Fiorino, G., Laterza, L., Viola, A., Bertani, L., Caprioli, F., Cappello, M., Barberio, B., Ricci, C., Balestrieri, P., Daperno, M., Pluchino, D., Rizzello, F., Scribano, M. L., Sablich, R., Pastorelli, L., Manguso, F., Variola, A., Di Sario, A., Grossi, L., Armuzzi, A., Ribaldone, D. G., Biscaglia, G., Buda, A., Mocci, G., Viscido, A., Di Paolo, M. C., Onali, S., Rodino, S., Coletta, M., Principi, M., Miranda, A., Amato, A., Bezzio, C., Petruzzellis, C., Mazzuoli, S., Festa, S., Sartini, A., Checchin, D., Fanigliulo, L., Gallina, S., Cesarini, M., Bodini, G., Stradella, D., Spagnuolo, R., Guidi, L., Savarino, E., Scrivo, B., Soru, P., Costa, F., Fries, W., Scaldaferri, F., Allocca, M., Pellegrini, L., Massari, A., Orlando, A., Pugliese D., Privitera G., Crispino F., Mezzina N., Castiglione F., Fiorino G., Laterza L., Viola A., Bertani L., Caprioli F., Cappello M., Barberio B., Ricci C., Balestrieri P., Daperno M., Pluchino D., Rizzello F., Scribano M.L., Sablich R., Pastorelli L., Manguso F., Variola A., Di Sario A., Grossi L., Armuzzi A., Ribaldone D.G., Biscaglia G., Buda A., Mocci G., Viscido A., Di Paolo M.C., Onali S., Rodino S., Coletta M., Principi M., Miranda A., Amato A., Bezzio C., Petruzzellis C., Mazzuoli S., Festa S., Sartini A., Checchin D., Fanigliulo L., Gallina S., Cesarini M., Bodini G., Stradella D., Spagnuolo R., Guidi L., Savarino E., Scrivo B., Soru P., Costa F., Fries W., Scaldaferri F., Allocca M., Pellegrini L., Massari A., and Orlando A.

Subjects
Crohn’s disease, Ulcerative, Antibodies, Monoclonal, Humanized, biologics (IBD), immunosuppression, ulcerative colitis, Aged, Chronic Disease, Colitis, Ulcerative, Crohn Disease, Humans, Prospective Studies, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Gastrointestinal Agents, Inflammatory Bowel Diseases, Antibodies, Monoclonal, Pharmacology (medical), Humanized, Settore MED/12 - Gastroenterologia, Hepatology, Gastroenterology, Colitis
Abstract

Background: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real-life data have been reported in this population. Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients. Methods: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017. Elderly patients (≥65 years) were matched clinically 1:2 to nonelderly patients (18–64 years); the 2 groups were followed until drug discontinuation or June 2019. Results: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients (67.6% vs. 51.4%, p=0.02). No significant difference in effectiveness was observed between elderly and nonelderly CD patients (59.4% vs. 52.4%, p=0.32). Age ≥65 years was associated with lower persistence in UC; for CD, previous exposure to anti-TNF-α agents, Charlson comorbidity index >2 and moderate-to-severe clinical activity at baseline were associated with lower persistence. There were recorded 130 adverse events, with comparable rates between the two groups. A Charlson comorbidity index >2 was associated with an increased risk of adverse events. Conclusion: Vedolizumab can be considered a safe option in elderly IBD patients. Its effectiveness in elderly UC patients may be reduced, while no age-dependent effect on effectiveness was observed in CD.

Published
2022

21. Gut and mesenteric lymph node involvement in pediatric patients infected with human immunodeficiency virus

Author

Mantegazza C, Maconi G, Giacomet V, Furfaro F, Mameli C, Bezzio C, Monteleone M, Ramponi G, and Zuccotti GV

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Cecilia Mantegazza,1 Giovanni Maconi,2 Vania Giacomet,1 Federica Furfaro,2 Chiara Mameli,1 Cristina Bezzio,2 Michela Monteleone,2 Giulia Ramponi,1 Gian Vincenzo Zuccotti11Department of Paediatrics, 2Gastroenterology Unit, L Sacco University Hospital, Milan, ItalyBackground: The gastrointestinal tract is a primary target for human immunodeficiency virus (HIV). HIV infection causes a depletion of CD4+ T-lymphocytes in gut-associated lymphoid tissue and affects gastrointestinal mucosal integrity and permeability. The gastrointestinal tract has also been suggested as the main reservoir of HIV despite highly active antiretroviral therapy (HAART). We performed a prospective case-control study to assess gut involvement in HIV-infected patients, either naïve or on HAART, using noninvasive methods such as bowel ultrasound and fecal calprotectin.Methods: Thirty HIV-infected children and youth underwent the following tests: CD4+ T-cell count and HIV viral load, fecal calprotectin, and bowel ultrasound, with the latter evaluating bowel wall thickness and mesenteric lymph nodes. Fecal calprotectin and bowel ultrasound were also assessed in 30 healthy controls matched for age and sex. Fecal calprotectin was measured using a quantitative immunochromatographic point-of-care test, and concentrations ranging from 0 to 200 µg/g were considered to be normal reference values in children.Results: Fecal calprotectin was normal in 29 HIV-infected patients and was not significantly different from controls (mean values 63.8±42.5 µg/g and 68.3±40.5 µg/g, respectively; P=0.419), and did not correlate with HIV viral load, CD4+ T-cell absolute count and percentage, or HAART treatment. No significant changes were found on bowel ultrasound except for enlarged mesenteric lymph nodes, which were observed in seven HIV-infected patients (23.3%) and two controls (6.6%). This finding was significantly correlated with high HIV viral load (P=0.001) and low CD4+ T-cell percentage (P=0.004).Conclusion: HIV-infected children did not have significant biochemical or ultrasonographic signs of bowel inflammation. A few patients showed enlarged mesenteric lymph nodes, which correlated with uncontrolled HIV infection.Keywords: children, human immunodeficiency virus, fecal calprotectin, bowel ultrasound

Published
2014

22. Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy

Author

Vitello, A, Grova, M, Pugliese, D, Rizzello, F, Lanzarotto, F, Lavagna, A, Caccaro, R, Cappello, M, Viola, A, Ribaldone, Dg, Principi, M, Stasi, E, Scribano, Ml, Maida, M, Soriano, A, Bezzio, C, Bodini, G, Mocciaro, F, Privitera, Ac, Simondi, D, Giuffrida, E, D'Incà, R, Ricci, C, Gionchetti, P, Armuzzi, A, Orlando, A, Daperno, M, Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD, Vitello A., Grova M., Pugliese D., Rizzello F., Lanzarotto F., Lavagna A., Caccaro R., Cappello M., Viola A., Ribaldone D.G., Principi M., Stasi E., Scribano M.L., Maida M., Soriano A., Bezzio C., Bodini G., Mocciaro F., Privitera A.C., Simondi D., Giuffrida E., D'Inca R., Ricci C., Gionchetti P., Armuzzi A., Orlando A., and Daperno M.

Subjects
musculoskeletal diseases, Adult, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Effectiveness, Young Adult, Internal medicine, Adalimumab, Medicine, Humans, Adverse effect, skin and connective tissue diseases, Colectomy, Aged, Retrospective Studies, Real-world evidence, Hepatology, business.industry, Gastroenterology, Effectivene, Retrospective cohort study, Induction Chemotherapy, Middle Aged, medicine.disease, Ulcerative colitis, Discontinuation, Clinical Practice, Treatment Outcome, Italy, Safety, Concomitant, Colitis, Ulcerative, Female, Tumor Necrosis Factor Inhibitors, business, medicine.drug
Abstract

Background Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.0%). At week 8, clinical responses were observed in 177 cases (46.5%) and clinical remission in 136 cases (35.7%). At 12 months, remission was observed in 128 cases (33.6%). Overall, 44 patients required colectomy, and 170 patients (44.6%) were still taking adalimumab when data were collected. Variables associated with adalimumab discontinuation were concomitant steroid treatment, severe clinical-endoscopic activity at baseline, need for adalimumab intensification and drug-related adverse events. Variables associated with colectomy were concomitant steroid treatment and high baseline C-reactive protein. Conclusion Adalimumab is safe and effective for the treatment of ulcerative colitis.

Published
2021

23. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.

Author

Yanai, H., Kagramanova, A., Knyazev, O., Sabino, J., Haenen, S., Mantzaris, G.J., Mountaki, K., Armuzzi, A., Pugliese, D., Furfaro, F., Fiorino, G., Drobne, D., Kurent, T., Yassin, S., Maharshak, N., Castiglione, F., Sire, R. de, Nardone, O.M., Farkas, K., Molnar, T., Krznaric, Z., Brinar, M., Chashkova, E., Livne Margolin, M., Kopylov, U., Bezzio, C., Bar-Gil Shitrit, A., Lukas, M., Chaparro, M., Truyens, M., Nancey, S., Lobaton, T., Gisbert, J.P., Saibeni, S., Bacsúr, P., Bossuyt, P., Schulberg, J., Hoentjen, F., Viganò, C., Palermo, A., Torres, J., Revés, J., Karmiris, K., Velegraki, M., Savarino, E., Markopoulos, P., Tsironi, E., Ellul, P., Calviño Suárez, C., Weisshof, R., Ben-Hur, D., Naftali, T., Eriksson, C., Koutroubakis, I.E., Foteinogiannopoulou, K., Limdi, J.K., Liu, E., Surís, G., Calabrese, E., Zorzi, F., Filip, R., Ribaldone, D.G., Snir, Y., Goren, I., Banai-Eran, H., Broytman, Y., Amir Barak, H., Avni-Biron, I., Ollech, J.E., Dotan, I., haroni Golan, M. A, Yanai, H., Kagramanova, A., Knyazev, O., Sabino, J., Haenen, S., Mantzaris, G.J., Mountaki, K., Armuzzi, A., Pugliese, D., Furfaro, F., Fiorino, G., Drobne, D., Kurent, T., Yassin, S., Maharshak, N., Castiglione, F., Sire, R. de, Nardone, O.M., Farkas, K., Molnar, T., Krznaric, Z., Brinar, M., Chashkova, E., Livne Margolin, M., Kopylov, U., Bezzio, C., Bar-Gil Shitrit, A., Lukas, M., Chaparro, M., Truyens, M., Nancey, S., Lobaton, T., Gisbert, J.P., Saibeni, S., Bacsúr, P., Bossuyt, P., Schulberg, J., Hoentjen, F., Viganò, C., Palermo, A., Torres, J., Revés, J., Karmiris, K., Velegraki, M., Savarino, E., Markopoulos, P., Tsironi, E., Ellul, P., Calviño Suárez, C., Weisshof, R., Ben-Hur, D., Naftali, T., Eriksson, C., Koutroubakis, I.E., Foteinogiannopoulou, K., Limdi, J.K., Liu, E., Surís, G., Calabrese, E., Zorzi, F., Filip, R., Ribaldone, D.G., Snir, Y., Goren, I., Banai-Eran, H., Broytman, Y., Amir Barak, H., Avni-Biron, I., Ollech, J.E., Dotan, I., and haroni Golan, M. A

Abstract

Item does not contain fulltext, BACKGROUND: Endoscopic-post-operative-recurrence [ePOR] in Crohn's disease [CD] after ileocecal resection [ICR] is a major concern. We aimed to evaluate the effectiveness of early prophylaxis with biologics and to compare anti-tumour necrosis factor [anti-TNF] therapy to vedolizumab [VDZ] and ustekinumab [UST] in a real-world setting. METHODS: A retrospective multicentre study of CD-adults after curative ICR on early prophylaxis was undertaken. ePOR was defined as a Rutgeerts score [RS] ≥ i2 or colonic-segmental-SES-CD ≥ 6. Multivariable logistic regression was used to evaluate risk factors, and inverse probability treatment weighting [IPTW] was applied to compare the effectiveness between agents. RESULTS: The study included 297 patients (53.9% males, age at diagnosis 24 years [19-32], age at ICR 34 years [26-43], 18.5% smokers, 27.6% biologic-naïve, 65.7% anti-TNF experienced, 28.6% two or more biologics and 17.2% previous surgery). Overall, 224, 39 and 34 patients received anti-TNF, VDZ or UST, respectively. Patients treated with VDZ and UST were more biologic experienced with higher rates of previous surgery. ePOR rates within 1 year were 41.8%. ePOR rates by treatment groups were: anti-TNF 40.2%, VDZ 33% and UST 61.8%. Risk factors for ePOR at 1 year were: past-infliximab (adjusted odds ratio [adj.OR] = 1.73 [95% confidence interval, CI: 1.01-2.97]), past-adalimumab [adj.OR = 2.32 [95% CI: 1.35-4.01] and surgical aspects. After IPTW, the risk of ePOR within 1 year of VDZ vs anti-TNF or UST vs anti-TNF was comparable (OR = 0.55 [95% CI: 0.25-1.19], OR = 1.86 [95% CI: 0.79-4.38]), respectively. CONCLUSION: Prevention of ePOR within 1 year after surgery was successful in ~60% of patients. Patients treated with VDZ or UST consisted of a more refractory group. After controlling for confounders, no differences in ePOR risk were seen between anti-TNF prophylaxis and other groups.

Published
2022

26. PC.01.4 REDUCED IMMUNE RESPONSE INDUCED BY TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IG-IBD STUDY

Author

Macaluso, F.S., primary, Principi, M., additional, Facciotti, F., additional, Contaldo, A., additional, Todeschini, A., additional, Saibeni, S., additional, Bezzio, C., additional, Castiglione, F., additional, Nardone, O.M., additional, Spagnuolo, R., additional, Doldo, P., additional, Fantini, M.C., additional, Paba, S., additional, Riguccio, G., additional, Conforti, F.S., additional, Viganò, C., additional, Ascolani, M., additional, Bodini, G., additional, Milla, M., additional, Scardina, G., additional, Vernero, M., additional, Desideri, F., additional, Mannino, M., additional, Rizzo, G., additional, Caprioli, F.A., additional, and Orlando, A., additional

Published
2022
Full Text
View/download PDF

27. T.06.8 COMPARATIVE OBJECTIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB IN A REAL-LIFE COHORT OF ACTIVE CROHN’S DISEASE PATIENTS FAILURE TO TNF INHIBITORS

Author

Onali, S., primary, Pugliese, D., additional, Caprioli, F.A., additional, Orlando, A., additional, Biancone, L., additional, Nardone, O.M., additional, Imperatore, N., additional, Fiorino, G., additional, Cappello, M., additional, Viola, A., additional, Principi, M.B., additional, Bezzio, C., additional, Aratari, A., additional, Carparelli, S., additional, Mancuso, F., additional, Grossi, L., additional, Bodini, G., additional, Ribaldone, D., additional, Mocci, G., additional, Favale, A., additional, Grova, M., additional, Scucchi, L., additional, Segato, S., additional, Fries, W., additional, Castiglione, F., additional, Armuzzi, A., additional, and Fantini, M.C., additional

Published
2022
Full Text
View/download PDF

28. Autoimmune pancreatitis in patients with Inflammatory Bowel Disease: results from a multicentre ECCO CONFER cases series

Author

Eder, P. M., Verstock, B., Culver, E., Dragoni, G., Kredel, L. I., de Paredes, A. G. G., Kaniewska, M., Leibovitzh, H., Oracz, G., Ribaldone, D. G., Wypych, J., Badaoui, A., Rahier, J. F., Bezzio, C., Bossuyt, P., Falloon, K., Vozzo, C. F., Jess, T., Larsen, L., Olensen, S. S., Starzynska, T., Chaparro, M., Dror, D., Ellul, P., Gromny, I., Maciejewska, K., Peleg, N., Shitrit, A. B. G., Szwed, L., Talar-Wojnarowska, R., Snir, Y., Zittan, E., and Goren, I.

Published
2022

29. IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame

Author

Bezzio, C, Fiorino, G, Ribaldone, Dg, Armuzzi, A, Saibeni, S, Ricci, C, and and IG-IBD COVID-19 Study Group

Subjects
Settore MED/12 - Gastroenterologia, therapy, Inflammatory Bowel DIseasis, Flare, COVID-19, therapy, Gastroenterology, Immunology and Allergy, COVID-19, Inflammatory Bowel DIseasis, Flare
Abstract

Lay Summary This prospective case-control study investigated the impact of severe acute respiratory syndrome coronavirus 2 infection on inflammatory bowel disease course and looked for risk factors associated with flares. In the severe acute respiratory syndrome coronavirus 2 pandemic era, inflammatory bowel disease course is not influenced by infection, while therapy discontinuation is a risk factor for disease flare.

Published
2022

30. IBD and Covid-19 in Italy: comparisons between first and second pandemic wave

Author

Bezzio, C., Costa, S., Armuzzi, A., Furfaro, F., Ardizzone, S., Milla, M., Bossa, F., Orlando, A., Caprioli, F. A., Castiglione, F., Vigano, C., Ribaldone, D. G., Zingone, F., Monterubbianesi, R., Imperatore, N., Festa, S., Daperno, M., Scucchi, L., Ferronato, A., Pastorelli, L., Balestrieri, P., Ricci, C., Cappello, M., Felice, C., Coppini, F., Alvisi, P., Gerardi, V., Variola, A., Mazzuoli, S., Lenti, M. V., Alessandro Armuzzi, Buda, A., Micheli, F., Ciardo, V., Casella, G., Viscido, A., Bodini, G., Fiorino, G., Vernero, M., and Saibeni, S.

Subjects
covid-19, inflammatory bowel disease, outcomes
Published
2022

31. P384 Postoperative Endoscopic Recurrence In Patients With Crohn’s Disease After “Curative” Ileocecal Resection on Prophylaxis Treatment With Either Anti-TNFs, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study

Author

Yanai, H, primary, Amir Barak, H, additional, Kagramanova, A, additional, Knyazev, O, additional, Sabino, J, additional, Haenen, S, additional, Mantzaris, G J, additional, Mountaki, K, additional, Pugliese, D, additional, Armuzzi, A, additional, Furfaro, F, additional, Fiorino, G, additional, Drobne, D, additional, Kurent, T, additional, Yassin, S, additional, Maharshak, N, additional, Castiglione, F, additional, Nardone, O M, additional, de Sire, R, additional, Farkas, K, additional, Molnar, T, additional, Krznaric, Z, additional, Brinar, M, additional, Chashkova, E, additional, Margolin, M L, additional, Kopylov, U, additional, Bezzio, C, additional, Bar-Gil Shitrit, A, additional, Lukas, M, additional, Chaparro, M, additional, Truyens, M, additional, Nancey, S, additional, Revés, J, additional, Avni-Biron, I, additional, Ollech, J E, additional, Dotan, I, additional, and Aharoni Golan, M, additional

Published
2022
Full Text
View/download PDF

32. P260 Autoimmune pancreatitis in patients with Inflammatory Bowel Disease: results from a multicentre ECCO CONFER cases series

Author

Eder, P M, primary, Verstock, B, additional, Culver, E, additional, Dragoni, G, additional, Kredel, L I, additional, de Paredes, A G G, additional, Kaniewska, M, additional, Leibovitzh, H, additional, Oracz, G, additional, Ribaldone, D G, additional, Wypych, J, additional, Badaoui, A, additional, Rahier, J F, additional, Bezzio, C, additional, Bossuyt, P, additional, Falloon, K, additional, Vozzo, C F, additional, Jess, T, additional, Larsen, L, additional, Olensen, S S, additional, Starzyńska, T, additional, Chaparro, M, additional, Dror, D, additional, Ellul, P, additional, Gromny, I, additional, Maciejewska, K, additional, Peleg, N, additional, Shitrit, A B G, additional, Szwed, Ł, additional, Talar-Wojnarowska, R, additional, Snir, Y, additional, Zittan, E, additional, and Goren, I, additional

Published
2022
Full Text
View/download PDF

33. P268 IBD and Covid-19 in italy: comparisons between first and second pandemic wave

Author

Bezzio, C, primary, Costa, S, additional, Armuzzi, A, additional, Furfaro, F, additional, Ardizzone, S, additional, Milla, M, additional, Bossa, F, additional, Orlando, A, additional, Caprioli, F A, additional, Castiglione, F, additional, Viganò, C, additional, Ribaldone, D G, additional, Zingone, F, additional, Monterubbianesi, R, additional, Imperatore, N, additional, Festa, S, additional, Daperno, M, additional, Scucchi, L, additional, Ferronato, A, additional, Pastorelli, L, additional, Balestrieri, P, additional, Ricci, C, additional, Cappello, M, additional, Felice, C, additional, Coppini, F, additional, Alvisi, P, additional, Gerardi, V, additional, Variola, A, additional, Mazzuoli, S, additional, Lenti, M V, additional, Alessandro, S, additional, Buda, A, additional, Micheli, F, additional, Ciardo, V, additional, Casella, G, additional, Viscido, A, additional, Bodini, G, additional, Fiorino, G, additional, Vernero, M, additional, and Saibeni, S, additional

Published
2022
Full Text
View/download PDF

34. P613 Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn’s disease patients failure to TNF inhibitors

Author

Onali, S, primary, Pugliese, D, additional, Caprioli, F A, additional, Orlando, A, additional, Biancone, L, additional, Nardone, O M, additional, Imperatore, N, additional, Fiorino, G, additional, Cappello, M, additional, Viola, A, additional, Principi, M B, additional, Bezzio, C, additional, Aratari, A, additional, Carparelli, S, additional, Mazzuoli, S, additional, Manguso, F, additional, Grossi, L, additional, Bodini, G, additional, Ribaldone, D, additional, Mocci, G, additional, Minerba, L, additional, Favale, A, additional, Grova, M, additional, Scucchi, L, additional, Segato, S, additional, Fries, W, additional, Castiglione, F, additional, Armuzzi, A, additional, and Fantini, M C, additional

Published
2022
Full Text
View/download PDF

37. P150 Increased risk of ibd flare after sars-cov-2 infection. who’s the more guilty: viral infection or therapy withdrawal?

Author

Bezzio, C, primary, Guarino, A D, additional, Fiorino, G, additional, Armuzzi, A, additional, Ribaldone, D G, additional, Furfaro, F, additional, Pugliese, D, additional, Vernero, M, additional, Variola, A, additional, Gerardi, V, additional, Scucchi, L, additional, Viganò, C, additional, Caprioli, F A, additional, Roselli, J, additional, Coppini, F, additional, Ardizzone, S, additional, Onali, S, additional, Zingone, F, additional, Daperno, M, additional, Cortellezzi, C, additional, Carparelli, S, additional, Soriano, A, additional, Manes, G, additional, and Saibeni, S, additional

Published
2022
Full Text
View/download PDF

38. AF.154 NON-INVASIVE ASSESSMENT OF POSTOPERATIVE DISEASE RECURRENCE IN CROHN’S DISEASE: A MULTICENTER, PROSPECTIVE COHORT STUDY

Author

Furfaro, F., primary, Zilli, A., additional, Craviotto, V., additional, Aratari, A., additional, Bezzio, C., additional, Gilardi, D., additional, Loy, L., additional, D’Amico, F., additional, Saibeni, S., additional, Papi, C., additional, Peyrin–Biroulet, L., additional, Fiorino, G., additional, Danese, S., additional, and Allocca, M., additional

Published
2021
Full Text
View/download PDF

39. OC.09.5 LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN PATIENTS WITH REFRACTORY CROHN’S DISEASE: A MULTICENTER REALLIFE STUDY

Author

Scribano, M.L., primary, Aratari, A., additional, Neri, B., additional, Bezzio, C., additional, Balestrieri, P., additional, Falasco, G., additional, Camastra, C., additional, Pantanella, P., additional, Monterubbianesi, R., additional, Tullio, A., additional, Saibeni, S., additional, Papi, C., additional, Biancone, L., additional, Cosintino, R., additional, and Faggiani, R., additional

Published
2021
Full Text
View/download PDF

40. AF.52 LONG-TERM OUTCOME OF ACUTE SEVERE ULCERATIVE COLITIS RESPONSIVE TO INTRAVENOUS STEROID: A MULTICENTER IG-IBD STUDY

Author

Festa, S., primary, Scribano, M.L., additional, Aratari, A., additional, Bezzio, C., additional, Principi, M., additional, Pugliese, D., additional, Ribaldone, D.G., additional, Furfaro, F., additional, Mocci, G., additional, Spagnuolo, R., additional, Vernia, P., additional, Costa, F., additional, Cosintino, R., additional, De Biasio, F., additional, Saibeni, S., additional, Armuzzi, A., additional, and Papi, C., additional

Published
2021
Full Text
View/download PDF

41. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV 2 infection: an IG-IBD study

Author

Bezzio, C., Armuzzi, A., Furfaro, F., Ardizzone, S., Milla, M., Carparelli, S., Orlando, A., Caprioli, F. A., Castiglione, F., Vigano, C., Ribaldone, D. G., Zingone, F., Monterubbianesi, R., Imperatore, N., Festa, S., Daperno, M., Scucchi, L., Ferronato, A., Pastorelli, L., Balestrieri, P., Ricci, C., Cappello, M., Felice, C., Fiorino, G., Saibeni, S., Coppini, F., Alvisi, P., Gerardi, V., Variola, A., Mazzuoli, S., Lenti, M. V., Pugliese, D., Allocca, M., Ferretti, F., Roselli, J., Bossa, F., Giuliano, A., Piazza, N., Manes, G., Sartini, A., Buda, A., Micheli, F., Ciardo, V., Casella, G., Viscido, A., Bodini, G., Casini, V., Soriano, A., Amato, A., Grossi, L., Onali, S., Rottoli, M., Spagnuolo, R., Baroni, S., Cortelezzi, C. C., Baldoni, M., Vernero, M., Scaldaferri, F., Maconi, G., Guarino, A. D., Palermo, A., D'Inca, R., Scribano, M. L., Biancone, L., Carrozza, L., Ascolani, M., Costa, F., Di Sabatino, A., Zammarchi, I., Gottin, M., Conforti, F. S., Bezzio, Cristina, Armuzzi, Alessandro, Furfaro, Federica, Ardizzone, Sandro, Milla, Monica, Carparelli, Sonia, Orlando, Ambrogio, Caprioli, Flavio Andrea, Castiglione, Fabiana, Viganò, Chiara, Ribaldone, Davide Giuseppe, Zingone, Fabiana, Monterubbianesi, Rita, Imperatore, Nicola, Festa, Stefano, Daperno, Marco, Scucchi, Ludovica, Ferronato, Antonio, Pastorelli, Luca, Balestrieri, Paola, Ricci, Chiara, Cappello, Maria, Felice, Carla, Fiorino, Gionata, Saibeni, Simone, and Francesca Coppini, Patrizia Alvisi, Viviana Gerardi, Angela Variola, Silvia Mazzuoli, Marco Vincenzo Lenti, Daniela Pugliese, Mariangela Allocca, Francesca Ferretti, Jenny Roselli, Fabrizio Bossa, Alessandra Giuliano, Nicole Piazza, Gianpiero Manes, Alessandro Sartini, Andrea Buda, Federica Micheli, Valeria Ciardo, Giovanni Casella, Angelo Viscido, Giorgia Bodini, Valentina Casini, Alessandra Soriano, Arnaldo Amato, Laurino Grossi, Sara Onali, Matteo Rottoli, Rocco Spagnuolo, Stefania Baroni, Claudio Cortelezzi, Monia Baldoni, Marta Vernero, Franco Scaldaferri, Giovanni Maconi, Alessia Dalila Guarino, Andrea Palermo, Renata D'Incà, Maria Lia Scribano, Livia Biancone, Lucio Carrozza, Marta Ascolani, Francesco Costa, Antonio Di Sabatino, Irene Zammarchi, Matteo Gottin, Francesco Simone Conforti

Subjects
medicine.medical_specialty, Settore MED/12 - GASTROENTEROLOGIA, IBD, Population, Ulcerative, Disease, Lower risk, Asymptomatic, Inflammatory bowel disease, Aged, Humans, SARS-CoV-2, Tumor Necrosis Factor Inhibitors, COVID-19, Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, IBD Treatments and Sars‐cov‐2 Infection, Internal medicine, medicine, biologics, Pharmacology (medical), education, therapy, education.field_of_study, Hepatology, business.industry, INFLAMMATORY BOWEL DISEASE, Gastroenterology, medicine.disease, Colitis, Ulcerative colitis, Pneumonia, Original Article, medicine.symptom, business, Cohort study
Abstract

Summary Background Older age and comorbidities are the main risk factors for adverse COVID‐19 outcomes in patients with inflammatory bowel disease (IBD). The impact of IBD medications is still under investigation. Aims To assess risk factors for adverse outcomes of COVID‐19 in IBD patients and use the identified risk factors to build risk indices. Methods Observational cohort study. Univariable and multivariable logistic regression was used to identify risk factors associated with pneumonia, hospitalisation, need for ventilatory support, and death. Results Of the 937 patients (446 with ulcerative colitis [UC]) evaluated, 128 (13.7%) had asymptomatic SARS‐CoV‐2 infection, 664 (70.8%) had a favourable course, and 135 (15.5%) had moderate or severe COVID‐19. In UC patients, obesity, active disease and comorbidities were significantly associated with adverse outcomes. In patients with Crohn's disease (CD), age, obesity, comorbidities and an additional immune‐mediated inflammatory disease were identified as risk factors. These risk factors were incorporated into two indices to identify patients with UC or CD with a higher risk of adverse COVID‐19 outcomes. In multivariable analyses, no single IBD medication was associated with poor COVID‐19 outcomes, but anti‐TNF agents were associated with a lower risk of pneumonia in UC, and lower risks of hospitalisation and severe COVID‐19 in CD. Conclusion The course of COVID‐19 in patients with IBD is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID‐19 outcomes. IBD medications do not pose additional risks. The risk indices may help to identify patients who should be prioritised for COVID‐19 re‐vaccination or for therapies for SARS‐CoV‐2 infection., The course of COVID‐19 in patients with IBD patients is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID‐19 outcomes. IBD medications do not pose additional risks.

Published
2021

42. Lower incidenze of COVID-19 in patients with Inflammatory Bowel Diseases on biologic therapy: results from a multicenter retrospective, observational study in Lombardy, Italy

Author

Ardizzone, S, Ferretti, F, Monico, Mc, Carvalhas Gabrielli AM, Carmagnola, S, Bezzio, C, Bosani, M, Caprioli, F, Mazza, S, Casini, V, Cassinotti, A, Cosimo, P, Di Sabatino, A, Lenti, M, Pastorelli, L, Ricci, C, Sarzi Puttini, P, Vecchi, M5, and Maconi, G

Subjects
SARS-CoV-2, COVID-19, Inflammatory bowel disease, Biologic therapy
Published
2021

43. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population.

Author

Ardizzone S., Saibeni S., Alicante S., Ferretti F., Rizzardini G., Galli M., Maconi G., Bosetti C., De Monti A., Boyapati R.K., Shelton E., Piazza N., Carvalhas Gabrielli A.M., Lenti M.V., Bezzio C., Ricci C., Greco S., Romeo S., Giangregorio F., Gridavilla D., Tagliani F., Massari A., Pastorelli L., Di Sabatino A., Ardizzone S., Saibeni S., Alicante S., Ferretti F., Rizzardini G., Galli M., Maconi G., Bosetti C., De Monti A., Boyapati R.K., Shelton E., Piazza N., Carvalhas Gabrielli A.M., Lenti M.V., Bezzio C., Ricci C., Greco S., Romeo S., Giangregorio F., Gridavilla D., Tagliani F., Massari A., Pastorelli L., and Di Sabatino A.

Abstract

Background: It is unclear whether patients with inflammatory bowel disease (IBD) are at increased risk of COVID-19. Objective(s): This observational study compared the prevalence of COVID-19 symptoms, diagnosis and hospitalization in IBD patients with a control population with non-inflammatory bowel disorders. Method(s): This multicentre study, included 2733 outpatients (1397 IBD patients and 1336 controls), from eight major gastrointestinal centres in Lombardy, Italy. Patients were invited to complete a web-based questionnaire regarding demographic, historical and clinical features over the previous 6 weeks. The prevalence of COVID-19 symptoms, diagnosis and hospitalization for COVID-19 was assessed. Result(s): 1810 patients (64%) responded to the questionnaire (941 IBD patients and 869 controls). IBD patients were significantly younger and of male sex than controls. NSAID use and smoking were more frequent in controls. IBD patients were more likely treated with vitamin-D and vaccinated for influenza. Highly probable COVID-19 on the basis of symptoms and signs was less frequent in the IBD group (3.8% vs 6.3%; OR:0.45, 95%CI:0.28-0.75). IBD patients had a lower rate of nasopharyngeal swab-PCR confirmed diagnosis (0.2% vs 1.2%; OR:0.14, 95%CI:0.03-0.67). There was no difference in hospitalization between the groups (0.1% vs 0.6%; OR:0.14, 95%CI:0.02-1.17). Conclusion(s): IBD patients do not have an increased risk of COVID-19 specific symptoms or more severe disease compared with a control group of gastroenterology patients.Copyright © 2021 Editrice Gastroenterologica Italiana S.r.l.

Published
2021

45. DOP34 Long-term outcome of Acute Severe Ulcerative Colitis responsive to intravenous steroid: A multicenter study of the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)

Author

Festa, S, primary, Scribano, M L, additional, Aratari, A, additional, Bezzio, C, additional, Principi, M, additional, Pugliese, D, additional, Ribaldone, D G, additional, Furfaro, F, additional, Mocci, G, additional, Spagnuolo, R, additional, Vernia, P, additional, Costa, F, additional, Cosintino, R, additional, De Biasio, F, additional, Saibeni, S, additional, Armuzzi, A, additional, and Papi, C, additional

Published
2021
Full Text
View/download PDF

46. P612 Lower incidence of COVID-19 in patients with Inflammatory Bowel Diseases treated with non-gut-selective biologic therapy: an observational multicentre study

Author

Ferretti, F, primary, Monico, M C, additional, Carvalhas Gabrielli, A M, additional, Carmagnola, S, additional, Bezzio, C, additional, Saibeni, S, additional, Bosani, M, additional, Caprioli, F, additional, Mazza, S, additional, Casini, V, additional, Cortelezzi, C, additional, Parravicini, M, additional, Cassinotti, A, additional, Cosimo, P, additional, Indriolo, A, additional, Di Sabatino, A, additional, Lenti, M V, additional, Pastorelli, L, additional, Conforti, F, additional, Ricci, C, additional, Sarzi-Puttini, P, additional, Vecchi, M, additional, Maconi, G, additional, and Ardizzone, S, additional

Published
2021
Full Text
View/download PDF

47. P327 Long-term effectiveness of ustekinumab in refractory Crohn’s disease: an Italian multicenter real-life study

Author

Scribano, M L, primary, Aratari, A, additional, Neri, B, additional, Bezzio, C, additional, Balestrieri, P, additional, Falasco, G, additional, Camastra, C, additional, Pantanella, P, additional, Monterubbianesi, R, additional, Tullio, A, additional, Saibeni, S, additional, Papi, C, additional, Biancone, L, additional, Cosintino, R, additional, and Faggiani, R, additional

Published
2021
Full Text
View/download PDF

48. P161 The impact of biologic therapies on Extra-Intestinal Manifestations in Inflammatory Bowel Disease: a multicentre observational study

Author

Ferretti, F, primary, Monico, M C, additional, Cannatelli, R, additional, Lenti, M V, additional, Di Sabatino, A, additional, Carmagnola, S, additional, Conforti, F, additional, Pastorelli, L, additional, Caprioli, F, additional, Bezzio, C, additional, Saibeni, S, additional, Mazza, S, additional, Vecchi, M, additional, Maconi, G, additional, and Ardizzone, S, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results